Therapeutic Targeting of TGFβ Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas.
Alexandros PapachristodoulouManuela SilginerMichael WellerHannah SchneiderKathy HasenbachMichel JanicotPatrick RothPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Targeting TGFβ expression with the novel LNA antisense oligonucleotides ISTH1047 or ISTH0047 results in strong antiglioma activity in vitro and in vivo, which may represent a promising approach to be examined in human patients with glioma.